EAM Investors’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.03M Buy
+68,609
New +$2.88M 0.36% 133
2021
Q1
Sell
-27,449
Closed -$1.34M 445
2020
Q4
$1.34M Sell
27,449
-9,865
-26% -$457K 0.22% 218
2020
Q3
$1.21M Buy
+37,314
New +$1.19M 0.29% 159
2019
Q4
Sell
-89,456
Closed -$2.15M 320
2019
Q3
$2.15M Sell
89,456
-65,325
-42% -$1.74M 0.57% 49
2019
Q2
$4.41M Sell
154,781
-41,812
-21% -$1.04M 1.08% 3
2019
Q1
$4.92M Sell
196,593
-29,328
-13% -$560K 1.21% 2
2018
Q4
$2.84M Buy
225,921
+152,081
+206% +$1.8M 0.77% 23
2018
Q3
$705K Buy
+73,840
New +$814K 0.1% 274
2017
Q3
Sell
-50,227
Closed -$418K 349
2017
Q2
$418K Sell
50,227
-17,784
-26% -$145K 0.07% 282
2017
Q1
$624K Buy
+68,011
New +$556K 0.1% 270
2015
Q3
Sell
-148,324
Closed -$1.65M 342
2015
Q2
$1.65M Buy
+148,324
New +$1.46M 0.19% 212

Other funds holding VCYT

EAM Investors's VCYT Position: Q2 2026 in Review

EAM Investors opened a new position in Veracyte (VCYT) in Q2 2026: 68,609 shares worth $4.03M. The stake represents 0.36% of the portfolio and ranks #133 among its holdings. This is a return to the name: EAM Investors previously reported a position in VCYT as recently as Q4 2020.

EAM Investors first reported a position in VCYT in Q2 2015 and has held it in 11 quarters since. The position peaked at $4.92M in Q1 2019. 370 funds tracked by Wall St. Rank hold VCYT as of Q2 2026.

  • EAM Investors held 68,609 shares of Veracyte worth $4.03M as of Q2 2026.
  • Veracyte was a new EAM Investors position in Q2 2026.
  • Veracyte made up 0.36% of EAM Investors's portfolio in Q2 2026, its #133 holding.
  • EAM Investors first reported a position in Veracyte in Q2 2015 and has held it in 11 quarters since.
  • EAM Investors's Veracyte position peaked at $4.92M in Q1 2019.
  • 370 funds tracked by Wall St. Rank held Veracyte as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.